Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

  • ID: 2254396
  • SWOT Analysis
  • Region: Sweden
  • 52 pages
  • GlobalData
  • Swedish Orphan Biovitrum AB
1 of 5

FEATURED COMPANIES

  • AMAG Pharmaceuticals Inc
  • BioGaia AB
  • Hansa Medical AB
  • Oasmia Pharmaceutical AB
  • MORE
Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on haemophilia, inflammation and genetic and metabolic diseases. The company’s products include Alprolix, Ammonaps, Elocta, Kepivance, Kineret and Orfadin. Sobi also manufactures and markets specialty and rare disease products for partner companies. It has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB Key Recent Developments

Apr 26, 2018: Sobi publishes the report for the first quarter 2018
Apr 17, 2018: Sobi publishes 2017 Annual and Sustainability Report
Apr 03, 2018: Fredrik Wetterlundh joins Sobi as Head of Human Resources
Feb 28, 2018: Sobi Launches Enhanced Corporate Sustainability Initiative
Feb 26, 2018: Swedish Orphan Biovitrum Appoints Henrik Stenqvist As New Chief Financial Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AMAG Pharmaceuticals Inc
  • BioGaia AB
  • Hansa Medical AB
  • Oasmia Pharmaceutical AB
  • MORE
Section 1 - About the Company
  • Swedish Orphan Biovitrum AB - Key Facts
  • Swedish Orphan Biovitrum AB - Key Employees
  • Swedish Orphan Biovitrum AB - Key Employee Biographies
  • Swedish Orphan Biovitrum AB - Major Products and Services
  • Swedish Orphan Biovitrum AB - History
  • Swedish Orphan Biovitrum AB - Company Statement
  • Swedish Orphan Biovitrum AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Swedish Orphan Biovitrum AB - Business Description
  • Business Segment: Haemophilia
  • Overview
  • Performance
  • Business Segment: ReFacto
  • Overview
  • Performance
  • Business Segment: Specialty Care
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: MENAR
  • Performance
  • Geographical Segment: North America
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Swedish Orphan Biovitrum AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Swedish Orphan Biovitrum AB - Strengths
  • Swedish Orphan Biovitrum AB - Weaknesses
  • Swedish Orphan Biovitrum AB - Opportunities
  • Swedish Orphan Biovitrum AB - Threats
  • Swedish Orphan Biovitrum AB - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Swedish Orphan Biovitrum AB, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 26, 2018: Sobi publishes the report for the first quarter 2018
  • Apr 17, 2018: Sobi publishes 2017 Annual and Sustainability Report
  • Apr 03, 2018: Fredrik Wetterlundh joins Sobi as Head of Human Resources
  • Feb 28, 2018: Sobi Launches Enhanced Corporate Sustainability Initiative
  • Feb 22, 2018: Sobi publishes its report for the fourth quarter and full-year 2017
  • Feb 07, 2018: The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's™ Extended Half-life Therapies
  • Feb 07, 2018: Time to Elevate Protection in Haemophilia Care: New Data From Sobi
  • Oct 25, 2017: Sobi publishes its report for the third quarter 2017
  • Oct 24, 2017: Sobi establishes new leadership structure and appoints Torbjorn Hallberg as General Counsel
  • Oct 06, 2017: Norbert Oppitz joins Sobi as new Senior Vice President, Specialty Care
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Swedish Orphan Biovitrum AB, Key Facts
  • Swedish Orphan Biovitrum AB, Key Employees
  • Swedish Orphan Biovitrum AB, Key Employee Biographies
  • Swedish Orphan Biovitrum AB, Major Products and Services
  • Swedish Orphan Biovitrum AB, History
  • Swedish Orphan Biovitrum AB, Subsidiaries
  • Swedish Orphan Biovitrum AB, Key Competitors
  • Swedish Orphan Biovitrum AB, Ratios based on current share price
  • Swedish Orphan Biovitrum AB, Annual Ratios
  • Swedish Orphan Biovitrum AB, Annual Ratios (Cont...1)
  • Swedish Orphan Biovitrum AB, Annual Ratios (Cont...2)
  • Swedish Orphan Biovitrum AB, Interim Ratios
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Swedish Orphan Biovitrum AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Swedish Orphan Biovitrum AB, Performance Chart (2013 - 2017)
  • Swedish Orphan Biovitrum AB, Ratio Charts
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Slottsviken Fastighetsaktiebolag
  • Oasmia Pharmaceutical AB
  • New Nordic Healthbrands AB
  • Hansa Medical AB
  • Fastilium Property Group AB
  • BioGaia AB
  • AMAG Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll